Genomics of Emerging Infectious Disease: A PLoS Collection
暂无分享,去创建一个
[1] Rajesh Gupta,et al. Can an Infectious Disease Genomics Project Predict and Prevent the Next Pandemic? , 2009, PLoS biology.
[2] N. Salama,et al. Helicobacter pylori's Unconventional Role in Health and Disease , 2009, PLoS pathogens.
[3] G. Dougan,et al. The Key Role of Genomics in Modern Vaccine and Drug Design for Emerging Infectious Diseases , 2009, PLoS genetics.
[4] A. Osterhaus,et al. The Application of Genomics to Emerging Zoonotic Viral Diseases , 2009, PLoS pathogens.
[5] Makedonka Mitreva,et al. Helminth Genomics: The Implications for Human Health , 2009, PLoS neglected tropical diseases.
[6] I. Comas,et al. The Past and Future of Tuberculosis Research , 2009, PLoS pathogens.
[7] A. Mchardy,et al. The Role of Genomics in Tracking the Evolution of Influenza A Virus , 2009, PLoS pathogens.
[8] Jacques Ravel,et al. The Role of Genomics in the Identification, Prediction, and Prevention of Biological Threats , 2009, PLoS biology.
[9] E. Harris,et al. Molecular Genomic Approaches to Infectious Diseases in Resource-Limited Settings , 2009, PLoS medicine.
[10] D. Falush. Toward the Use of Genomics to Study Microevolutionary Change in Bacteria , 2009, PLoS genetics.
[11] Edward C. Holmes,et al. Discovering the Phylodynamics of RNA Viruses , 2009, PLoS Comput. Biol..
[12] Siv G. E. Andersson,et al. Computational Resources in Infectious Disease: Limitations and Challenges , 2009, PLoS Comput. Biol..
[13] Wim G. J. Hol,et al. The Role of Medical Structural Genomics in Discovering New Drugs for Infectious Diseases , 2009, PLoS Comput. Biol..
[14] Rino Rappuoli,et al. Vaccinology in the genome era. , 2009, The Journal of clinical investigation.
[15] Brian Pease,et al. Discovery of Leukotriene A4 Hydrolase Inhibitors Using Metabolomics Biased Fragment Crystallography† , 2009, Journal of medicinal chemistry.
[16] T. Willson,et al. Open access chemical and clinical probes to support drug discovery. , 2009, Nature chemical biology.
[17] Kristina M Smith,et al. Native chromatin immunoprecipitation (N-ChIP) and ChIP-Seq of Schistosoma mansoni: Critical experimental parameters. , 2009, Molecular and biochemical parasitology.
[18] Gavin J. D. Smith,et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic , 2009, Nature.
[19] K. Jansen,et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. , 2009, Vaccine.
[20] R. Jacobson,et al. Application of pharmacogenomics to vaccines. , 2009, Pharmacogenomics.
[21] M. Taussig,et al. Protein microarrays: high-throughput tools for proteomics , 2009, Expert review of proteomics.
[22] B. Staels,et al. Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens , 2009, Nature.
[23] C. Schulze-Briese,et al. Crystal structure of Ultralente—A microcrystalline insulin suspension , 2009, Proteins.
[24] Ruben Abagyan,et al. Structure‐Based Approaches to Antibiotic Drug Discovery , 2009, Current protocols in microbiology.
[25] J. Kawai,et al. Direct Metagenomic Detection of Viral Pathogens in Nasal and Fecal Specimens Using an Unbiased High-Throughput Sequencing Approach , 2009, PloS one.
[26] S. Miller,et al. The role of infections in autoimmune disease , 2009, Clinical and experimental immunology.
[27] A. Fenwick. Host-parasite relations and implications for control. , 2009, Advances in parasitology.
[28] I. Margarit,et al. Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. , 2009, The Journal of infectious diseases.
[29] Akane Kawamura,et al. Arylamine N-acetyltransferases: structural and functional implications of polymorphisms. , 2008, Toxicology.
[30] J. Musser,et al. Sequence variation in group A Streptococcus pili and association of pilus backbone types with lancefield T serotypes. , 2008, The Journal of infectious diseases.
[31] S. Ram,et al. Binding of Complement Factor H (fH) to Neisseria meningitidis Is Specific for Human fH and Inhibits Complement Activation by Rat and Rabbit Sera , 2008, Infection and Immunity.
[32] Andrew D. Hamilton,et al. alpha-Helix mimetics as inhibitors of protein-protein interactions. , 2008, Biochemical Society transactions.
[33] L. Pena,et al. Deceptive imprinting and immune refocusing in vaccine design. , 2008, Vaccine.
[34] Yoav Freund,et al. Image-based crystal detection: a machine-learning approach , 2008, Acta crystallographica. Section D, Biological crystallography.
[35] Rino Rappuoli,et al. Structure-based antigen design: a strategy for next generation vaccines , 2008, Trends in Biotechnology.
[36] P. Nollert,et al. The plug-based nanovolume Microcapillary Protein Crystallization System (MPCS) , 2008, Acta crystallographica. Section D, Biological crystallography.
[37] R. Rappuoli,et al. Factor H-Binding Protein Is Important for Meningococcal Survival in Human Whole Blood and Serum and in the Presence of the Antimicrobial Peptide LL-37 , 2008, Infection and Immunity.
[38] Julie McMurry,et al. Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. , 2008, Current opinion in pharmacology.
[39] Gangqiao Zhou,et al. Infectious disease in the genomic era. , 2008, Annual review of genomics and human genetics.
[40] M. Marra,et al. Applications of next-generation sequencing technologies in functional genomics. , 2008, Genomics.
[41] A. Bhagwat,et al. Methods and tools for comparative genomics of foodborne pathogens. , 2008, Foodborne pathogens and disease.
[42] J. Sarles,et al. Molecular Detection of Multiple Emerging Pathogens in Sputa from Cystic Fibrosis Patients , 2008, PloS one.
[43] J. Wain,et al. High-throughput sequencing provides insights into genome variation and evolution in Salmonella Typhi , 2008, Nature Genetics.
[44] P. Gajer,et al. The Pangenome Structure of Escherichia coli: Comparative Genomic Analysis of E. coli Commensal and Pathogenic Isolates , 2008, Journal of bacteriology.
[45] William Martin,et al. Epitope-Based Immunome-Derived Vaccines: A Strategy for Improved Design and Safety , 2008, Clinical Applications of Immunomics.
[46] D. Granoff,et al. Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin. , 2008, The Journal of infectious diseases.
[47] Chao Zhang,et al. An integrated platform of genomic assays reveals small-molecule bioactivities. , 2008, Nature chemical biology.
[48] Lei Tang,et al. Shape shifting leads to small-molecule allosteric drug discovery. , 2008, Chemistry & biology.
[49] William Martin,et al. Identification of immunogenic HLA-B7 "Achilles' heel" epitopes within highly conserved regions of HIV. , 2008, Vaccine.
[50] A. Kusalik,et al. Massive peptide sharing between viral and human proteomes , 2008, Peptides.
[51] D. K. Kaushik,et al. Developing Antibacterial Vaccines in Genomics and Proteomics Era , 2008, Scandinavian journal of immunology.
[52] C. Donati,et al. A Second Pilus Type in Streptococcus pneumoniae Is Prevalent in Emerging Serotypes and Mediates Adhesion to Host Cells , 2008, Journal of bacteriology.
[53] M. Congreve,et al. Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.
[54] Jianli Dong,et al. Emerging Pathogens: Challenges and Successes of Molecular Diagnostics , 2008, The Journal of Molecular Diagnostics.
[55] R. Vierkant,et al. Human Leukocyte Antigen and Cytokine Receptor Gene Polymorphisms Associated With Heterogeneous Immune Responses to Mumps Viral Vaccine , 2008, Pediatrics.
[56] P. Nordlund,et al. The use of systematic N- and C-terminal deletions to promote production and structural studies of recombinant proteins. , 2008, Protein expression and purification.
[57] S. Ram,et al. Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. , 2008, The Journal of infectious diseases.
[58] Yanhui Hu,et al. Production and sequence validation of a complete full length ORF collection for the pathogenic bacterium Vibrio cholerae , 2008, Proceedings of the National Academy of Sciences.
[59] M. Kalin,et al. Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies , 2008, The Journal of experimental medicine.
[60] Mark Harris,et al. Data management in structural genomics: an overview. , 2008, Methods in molecular biology.
[61] David Baker,et al. Structural genomics of pathogenic protozoa: an overview. , 2008, Methods in molecular biology.
[62] Christopher L. McClendon,et al. Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.
[63] Rino Rappuoli,et al. Bridging the knowledge gaps in vaccine design , 2007, Nature Biotechnology.
[64] E. Winzeler,et al. Genomics, systems biology and drug development for infectious diseases. , 2007, Molecular bioSystems.
[65] K. Reynolds,et al. Antibacterial targets in fatty acid biosynthesis. , 2007, Current opinion in microbiology.
[66] Glyn Williams,et al. Fragment-based screening using X-ray crystallography and NMR spectroscopy. , 2007, Current opinion in chemical biology.
[67] D. O'Kane,et al. Translation of Pharmacogenetics into Clinically Relevant Testing Modalities , 2007, Clinical pharmacology and therapy.
[68] M. Katze,et al. Functional Genomics Highlights Differential Induction of Antiviral Pathways in the Lungs of SARS-CoV–Infected Macaques , 2007, PLoS pathogens.
[69] T Neumann,et al. SPR-based fragment screening: advantages and applications. , 2007, Current topics in medicinal chemistry.
[70] D. Dimitrov,et al. Structure and Function of the HIV Envelope Glycoprotein as Entry Mediator, Vaccine Immunogen, and Target for Inhibitors , 2007, Advances in Pharmacology.
[71] E. Querol,et al. Pathogen Proteins Eliciting Antibodies Do Not Share Epitopes with Host Proteins: A Bioinformatics Approach , 2007, PloS one.
[72] R. Rappuoli,et al. The pan-genome: towards a knowledge-based discovery of novel targets for vaccines and antibacterials. , 2007, Drug discovery today.
[73] Pierre Baldi,et al. Immunodominant Francisella tularensis antigens identified using proteome microarray. ©Crown Copyright 2007 Dstl , 2007, Proteomics.
[74] E. Davioud‐Charvet,et al. Thioredoxin Glutathione Reductase from Schistosoma mansoni: An Essential Parasite Enzyme and a Key Drug Target , 2007, PLoS medicine.
[75] D. Kanduc,et al. Non-redundant peptidomes from DAPs: towards "the vaccine"? , 2007, Autoimmunity reviews.
[76] K. Lundstrom,et al. Structural genomics and drug discovery , 2007, Journal of cellular and molecular medicine.
[77] J. Casanova,et al. Human genetics of infectious diseases: a unified theory , 2007, The EMBO journal.
[78] Tongqing Zhou,et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120 , 2007, Nature.
[79] A. Goldman,et al. A complete structural description of the catalytic cycle of yeast pyrophosphatase. , 2007, Biochemistry.
[80] Haruki Nakamura,et al. The worldwide Protein Data Bank (wwPDB): ensuring a single, uniform archive of PDB data , 2006, Nucleic Acids Res..
[81] M. Pucci. Novel Genetic Techniques and Approaches in the Microbial Genomics Era , 2007, Drugs in R&D.
[82] Julius Rebek,et al. Heterocyclic alpha-helix mimetics for targeting protein-protein interactions. , 2007, Bioorganic & medicinal chemistry letters.
[83] D. Pompliano,et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.
[84] R. Rappuoli,et al. Streptococcus pneumoniae Pilus Subunits Protect Mice against Lethal Challenge , 2006, Infection and Immunity.
[85] D. Erlanson. Fragment-based lead discovery: a chemical update. , 2006, Current opinion in biotechnology.
[86] George T Detitta,et al. Thermofluor-based high-throughput stability optimization of proteins for structural studies. , 2006, Analytical biochemistry.
[87] T. Earnest,et al. Using fragment cocktail crystallography to assist inhibitor design of Trypanosoma brucei nucleoside 2-deoxyribosyltransferase. , 2006, Journal of medicinal chemistry.
[88] Jenefer M Blackwell,et al. Genetic susceptibility to infectious diseases: big is beautiful, but will bigger be even better? , 2006, The Lancet Infectious Diseases.
[89] R. Rappuoli,et al. A universal vaccine for serogroup B meningococcus. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[90] Rino Rappuoli,et al. Pili in Gram-positive pathogens , 2006, Nature Reviews Microbiology.
[91] David H Perlman,et al. The Meningococcal Vaccine Candidate GNA1870 Binds the Complement Regulatory Protein Factor H and Enhances Serum Resistance , 2006, The Journal of Immunology.
[92] S. D. Mills. When will the genomics investment pay off for antibacterial discovery? , 2006, Biochemical pharmacology.
[93] Dong Hui Xu,et al. Automated classification of protein crystallization images using support vector machines with scale-invariant texture and Gabor features. , 2006, Acta crystallographica. Section D, Biological crystallography.
[94] R. Rappuoli,et al. A pneumococcal pilus influences virulence and host inflammatory responses. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[95] G. Bensi,et al. Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome , 2006, Nature Biotechnology.
[96] Paul Kellam,et al. Attacking pathogens through their hosts , 2006, Genome Biology.
[97] G. Grandi. Genomics and proteomics in reverse vaccines. , 2005, Methods of biochemical analysis.
[98] Daniela Barlocco,et al. Privileged structures as leads in medicinal chemistry. , 2006, Current medicinal chemistry.
[99] G. Bensi,et al. Group A Streptococcus produce pilus-like structures containing protective antigens and Lancefield T antigens , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[100] Christoph Dehio,et al. Signature-tagged mutagenesis: technical advances in a negative selection method for virulence gene identification. , 2005, Current opinion in microbiology.
[101] Jaideep P. Sundaram,et al. Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome". , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[102] D. Butler. Flu researchers slam US agency for hoarding data , 2005, Nature.
[103] H. Tettelin,et al. Identification of a Universal Group B Streptococcus Vaccine by Multiple Genome Screen , 2005, Science.
[104] R. Rappuoli,et al. Genome Analysis Reveals Pili in Group B Streptococcus , 2005, Science.
[105] Stephen H Hughes,et al. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. , 2005, Progress in biophysics and molecular biology.
[106] Russell L. Marsden,et al. Progress of structural genomics initiatives: an analysis of solved target structures. , 2005, Journal of molecular biology.
[107] M. Hanner,et al. Antigenome technology: a novel approach for the selection of bacterial vaccine candidate antigens. , 2005, Vaccine.
[108] R. Rappuoli,et al. The impact of genomics on vaccine design. , 2005, Trends in biotechnology.
[109] Bjoern Peters,et al. A roadmap for the immunomics of category A-C pathogens. , 2005, Immunity.
[110] M. Rossmann,et al. Design, expression, and purification of a Flaviviridae polymerase using a high‐throughput approach to facilitate crystal structure determination , 2004, Protein science : a publication of the Protein Society.
[111] D. Pei,et al. Macrocyclic inhibitors for peptide deformylase: a structure-activity relationship study of the ring size. , 2004, Journal of medicinal chemistry.
[112] C. Martínez-A,et al. Statins Inhibit HIV-1 Infection by Down-regulating Rho Activity , 2004, The Journal of experimental medicine.
[113] M. Congreve,et al. Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.
[114] Takayoshi Kinoshita,et al. Structure-based design, synthesis, and structure-activity relationship studies of novel non-nucleoside adenosine deaminase inhibitors. , 2004, Journal of medicinal chemistry.
[115] J. Strohbach,et al. Non-peptidic HIV protease inhibitors. , 2004, Current topics in medicinal chemistry.
[116] M. Root,et al. HIV-1 gp41 as a target for viral entry inhibition. , 2004, Current pharmaceutical design.
[117] Rick Lyons,et al. The temporal expression profile of Mycobacterium tuberculosis infection in mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[118] Robert E. Thorne,et al. Microfabricated mounts for high-throughput macromolecular cryocrystallography , 2003 .
[119] M. Goldman,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Vaccination and Autoimmune Disease: What Is the Evidence? , 2022 .
[120] M. Congreve,et al. A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.
[121] P. Lam,et al. Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants. , 2003, Journal of medicinal chemistry.
[122] R. Ismagilov,et al. Screening of protein crystallization conditions on a microfluidic chip using nanoliter-size droplets. , 2003, Journal of the American Chemical Society.
[123] Rodrigo Lopez,et al. Multiple sequence alignment with the Clustal series of programs , 2003, Nucleic Acids Res..
[124] R. Haas,et al. Identification and Characterization of Helicobacter pylori Genes Essential for Gastric Colonization , 2003, The Journal of experimental medicine.
[125] E. Rubin,et al. Genes required for mycobacterial growth defined by high density mutagenesis , 2003, Molecular microbiology.
[126] Joseph R Luft,et al. A deliberate approach to screening for initial crystallization conditions of biological macromolecules. , 2003, Journal of structural biology.
[127] Jeannette Adu-Bobie,et al. Vaccination against Neisseria meningitidis Using Three Variants of the Lipoprotein GNA1870 , 2003, The Journal of experimental medicine.
[128] S. Quake,et al. A robust and scalable microfluidic metering method that allows protein crystal growth by free interface diffusion , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[129] Julie Wilson,et al. Towards the automated evaluation of crystallization trials. , 2002, Acta crystallographica. Section D, Biological crystallography.
[130] Y. Kiso,et al. HIV protease inhibitors: peptidomimetic drugs and future perspectives. , 2002, Current medicinal chemistry.
[131] S. Harrison,et al. Crystal structure of human calcineurin complexed with cyclosporin A and human cyclophilin , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[132] W. Hol,et al. Characterization and crystal structure of a high-affinity pentavalent receptor-binding inhibitor for cholera toxin and E. coli heat-labile enterotoxin. , 2002, Journal of the American Chemical Society.
[133] L. Huber,et al. Identification of vaccine candidate antigens of Staphylococcus aureus by serological proteome analysis , 2002, Proteomics.
[134] Earl W. Cornell,et al. An approach to rapid protein crystallization using nanodroplets , 2002 .
[135] R. Rappuoli,et al. Reverse vaccinology, a genome-based approach to vaccine development. , 2001 .
[136] D. O'Kane,et al. Gene expression microarrays: a 21st century tool for directed vaccine design. , 2001, Vaccine.
[137] Christoph M Tang,et al. Functional genomics of Neisseria meningitidis pathogenesis , 2000, Nature Medicine.
[138] M. Gelb,et al. Adenosine analogues as inhibitors of Trypanosoma brucei phosphoglycerate kinase: elucidation of a novel binding mode for a 2-amino-N(6)-substituted adenosine. , 2000, Journal of medicinal chemistry.
[139] Vicki L. Nienaber,et al. Discovering novel ligands for macromolecules using X-ray crystallographic screening , 2000, Nature Biotechnology.
[140] J. Wood,et al. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. , 2000, Chemistry & biology.
[141] J. Venter,et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. , 2000, Science.
[142] Stuart L. Schreiber,et al. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements , 1999, Nature Structural Biology.
[143] A. Goldman,et al. Evolutionary aspects of inorganic pyrophosphatase , 1999, FEBS letters.
[144] M. Gelb,et al. Selective tight binding inhibitors of trypanosomal glyceraldehyde-3-phosphate dehydrogenase via structure-based drug design. , 1998, Journal of medicinal chemistry.
[145] A. Steere,et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. , 1998, Science.
[146] A Wlodawer,et al. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. , 1998, Annual review of biophysics and biomolecular structure.
[147] N. Chirgadze,et al. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. , 1997, Journal of medicinal chemistry.
[148] S. Harrison,et al. Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.
[149] M. Rossmann,et al. The refined structure of human rhinovirus 16 at 2.15 A resolution: implications for the viral life cycle. , 1997, Structure.
[150] W G Laver,et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. , 1997, Journal of the American Chemical Society.
[151] Structure of Escherichia coli inorganic pyrophosphatase at 2.2 A resolution. , 1996, Acta crystallographica. Section D, Biological crystallography.
[152] R. Fleischmann,et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. , 1995, Science.
[153] M. Garneau,et al. A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo , 1994, Nature.
[154] T. Steitz,et al. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[155] W G Laver,et al. Three-dimensional structure of influenza A N9 neuraminidase and its complex with the inhibitor 2-deoxy 2,3-dehydro-N-acetyl neuraminic acid. , 1994, Journal of molecular biology.
[156] D. M. Ryan,et al. Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.
[157] T. Steitz,et al. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. , 1992, Science.
[158] D. Lipman,et al. National Center for Biotechnology Information , 2019, Springer Reference Medizin.
[159] A Wlodawer,et al. Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. , 1989, Science.
[160] John P. Overington,et al. X-ray analysis of HIV-1 proteinase at 2.7 Å resolution confirms structural homology among retroviral enzymes , 1989, Nature.
[161] M. Jaskólski,et al. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. , 1989, Science.
[162] M. Navia,et al. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1 , 1989, Nature.
[163] J. Felsenstein. Phylogenies from molecular sequences: inference and reliability. , 1988, Annual review of genetics.
[164] F. Sanger,et al. DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.